Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.49 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.47 |
| ▸ | PNP | P00491 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 2/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | HINT1 | P49773 | 1/20 | 0.43 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.42 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.42 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22646947 | 1.00 | POLB (0.52) | POLBP2RY2P2RY4P2RY6TAS1R3 | |
| SCHEMBL20924430 | 1.00 | POLB (0.52) | POLBP2RY2P2RY4P2RY6TAS1R3 | |
| SCHEMBL21609616 | 1.00 | POLB (0.52) | POLBP2RY2P2RY4P2RY6TAS1R3 | |
| SCHEMBL16004521 | 1.00 | POLB (0.52) | POLBP2RY2P2RY4P2RY6TAS1R3 | |
| SCHEMBL16004579 | 1.00 | POLB (0.52) | POLBP2RY2P2RY4P2RY6TAS1R3 | |
| SCHEMBL17448154 | 0.91 | POLB (0.48) | POLBP2RY2P2RY4P2RY6TAS1R3 | |
| SCHEMBL13664952 | 0.89 | GSK3A (0.55) | POLBP2RY2P2RY4P2RY6TAS1R3 | |
| SCHEMBL14614379 | 0.89 | GSK3A (0.55) | POLBP2RY2P2RY4P2RY6TAS1R3 | |
| SCHEMBL21314724 | 0.89 | GSK3A (0.55) | POLBP2RY2P2RY4P2RY6TAS1R3 | |
| SCHEMBL17446514 | 0.88 | P2RY1 (0.45) | POLBP2RY2P2RY4P2RY6TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200352976-A1 | HYPOMETHYLATING AGENTS FOR USE IN TREATMENT OF CANCER | ASTEX PHARMACEUTICALS, INC. | 2020-11-12 | — | — | US | disclosed |
| US-10517886-B2 | Drug formulations | ASTEX PHARMACEUTICALS, INC. (US) | 2019-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200352976-A1 | HYPOMETHYLATING AGENTS FOR USE IN TREATMENT OF CANCER | DNMT1, MGMT, UNG | POLB 82/4885P2RY2 3883/4885P2RY4 3761/4885 |
| US-10517886-B2 | Drug formulations | MCL1, DNMT3A, TET2 | POLB 677/4885P2RY2 4299/4885P2RY4 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.